MedTrace Logo

Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients

NCT03576235 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-09-19

No results posted yet for this study

Summary

In this study (SNUG trial), the investigators aim to investigate the anti-pruritic effect of PG102P in comparison with placebo in 80 patients undergoing HD.

Conditions

  • Uremic Pruritus

Interventions

DRUG

PG102P

Daily dose of 1.5g

DRUG

Placebo

Daily dose of placebo

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Ewha Womans University Mokdong Hospital

    collaborator OTHER

  • Severance Hospital

    collaborator OTHER

  • Chungnam National University Hospital

    collaborator OTHER

  • Gachon University Gil Medical Center

    collaborator OTHER

  • Kyungpook National University Hospital

    collaborator OTHER

  • DongGuk University

    collaborator OTHER

  • Seoul National University Boramae Hospital

    lead OTHER

Principal Investigators

  • Chun Soo Lim, MD, PhD · Seoul National University Boramae Medical Center, Seoul, Republic of Korea.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2019-01-31
Completion
2019-03-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03576235 on ClinicalTrials.gov